Innoviva, Inc. SEC filings INVA
Innoviva, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to Nov 27, 2012. Its latest annual report, Form 10-K, was filed on Feb 25, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Mar 24, 2026 | Mar 24, 2026 |
| DEFA14A | Additional proxy material | Apr 8, 2025 | — |
| DEF 14A | Proxy statement | Apr 8, 2025 | May 19, 2025 |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 17, 2024 |
| DEFA14A | Additional proxy material | May 17, 2023 | — |
| DEFA14A | Additional proxy material | May 1, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Mar 25, 2022 | Apr 25, 2022 |
| DEFA14A | Additional proxy material | May 5, 2021 | — |
| DEF 14A | Proxy statement | Apr 2, 2021 | May 14, 2021 |
| DEFA14A | Additional proxy material | Mar 31, 2020 | — |
| DEFA14A | Additional proxy material | Mar 12, 2020 | — |
| DEF 14A | Proxy statement | Mar 11, 2020 | Apr 24, 2020 |
| DEFA14A | Additional proxy material | Mar 13, 2019 | — |
| DEF 14A | Proxy statement | Mar 13, 2019 | Apr 24, 2019 |
| DEF 14A | Proxy statement | Mar 23, 2018 | Apr 24, 2018 |
| DEFA14A | Additional proxy material | Apr 20, 2017 | — |
| DEFA14A | Additional proxy material | Apr 19, 2017 | — |
| DEFA14A | Additional proxy material | Apr 18, 2017 | — |
| DEFA14A | Additional proxy material | Apr 17, 2017 | — |
| DEFA14A | Additional proxy material | Apr 14, 2017 | — |
| DEFA14A | Additional proxy material | Apr 13, 2017 | — |
| DEFA14A | Additional proxy material | Apr 12, 2017 | — |
| DEFA14A | Additional proxy material | Apr 10, 2017 | — |
| DEFA14A | Additional proxy material | Apr 7, 2017 | — |
| DEFA14A | Additional proxy material | Apr 3, 2017 | — |
| DEFA14A | Additional proxy material | Apr 3, 2017 | — |
| DEFA14A | Additional proxy material | Apr 3, 2017 | — |
| DEFA14A | Additional proxy material | Mar 29, 2017 | — |
| DEFA14A | Additional proxy material | Mar 29, 2017 | — |
| DEFA14A | Additional proxy material | Mar 29, 2017 | — |
| DEFA14A | Additional proxy material | Mar 28, 2017 | — |
| DEFA14A | Additional proxy material | Mar 28, 2017 | — |
| DEFA14A | Additional proxy material | Mar 22, 2017 | — |
| DEFA14A | Additional proxy material | Mar 22, 2017 | — |
| DEFA14A | Additional proxy material | Mar 13, 2017 | — |
| DEFA14A | Additional proxy material | Mar 7, 2017 | — |
| DEFA14A | Additional proxy material | Mar 7, 2017 | — |
| DEF 14A | Proxy statement | Mar 25, 2016 | Apr 26, 2016 |
| PRE 14A | Preliminary proxy statement | Mar 10, 2016 | Apr 27, 2016 |
| DEF 14A | Proxy statement | Mar 24, 2015 | Apr 24, 2015 |
| DEF 14A | Proxy statement | Apr 15, 2014 | May 22, 2014 |
| DEF 14A | Proxy statement | Mar 12, 2013 | Apr 23, 2013 |
Showing 44 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INVA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Burlingame, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1080014
- Former names
- THERAVANCE INC (until Dec 7, 2015); ADVANCED MEDICINE INC (until Aug 2, 2000)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.